Liminal BioSciences (NASDAQ:LMNL – Get Rating) and Capricor Therapeutics (NASDAQ:CAPR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Liminal BioSciences and Capricor Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Get Liminal BioSciences alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liminal BioSciences | $510,000.00 | 29.83 | $10.28 million | $1.51 | 0.32 |
| Capricor Therapeutics | $250,000.00 | 577.49 | -$20.02 million | ($1.04) | -5.70 |
Liminal BioSciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Liminal BioSciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Liminal BioSciences has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.84, suggesting that its stock price is 384% more volatile than the S&P 500.Insider & Institutional Ownership
0.9% of Liminal BioSciences shares are owned by institutional investors. Comparatively, 10.4% of Capricor Therapeutics shares are owned by institutional investors. 9.0% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Liminal BioSciences and Capricor Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Liminal BioSciences | 3,107.45% | -114.78% | -33.39% |
| Capricor Therapeutics | N/A | -89.89% | -48.31% |
Analyst Recommendations
This is a breakdown of current ratings for Liminal BioSciences and Capricor Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liminal BioSciences | 0 | 0 | 0 | 0 | N/A |
| Capricor Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Capricor Therapeutics has a consensus target price of $15.00, indicating a potential upside of 152.95%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Liminal BioSciences.
Summary
Capricor Therapeutics beats Liminal BioSciences on 7 of the 13 factors compared between the two stocks.
About Liminal BioSciences
(Get Rating)
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
About Capricor Therapeutics
(Get Rating)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Liminal BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminal BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.